Table II.
CT antigen expression in patients with papillary and follicular carcinoma.
| P | Gender | Age, years | Disease | Size, cm | Tumor stage | Positive lymph node | Metastasis | Stage grouping | Angiolymphatic invasion | Extra-thyroidal extension | Multi MAGE-A | CT7 (MAGE-C1) | GAGE | CTAG1B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 23 | Papillary | 3.0 | T2N1aM0 | Yes | Yes | III | No | No | – | – | – | – |
| 2 | F | 54 | Papillary | 2.5 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 3 | F | 34 | Papillary | 1.9 | T1N0M0 | No | No | I | No | No | – | – | f | – |
| 4 | F | 45 | Papillary | 3.2 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 5 | F | 47 | Papillary | 2.5 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 6 | M | 76 | Papillary | 3.5 | T2N1aM0 | Yes | Yes | III | Yes | Yes | – | – | – | – |
| 7 | F | 49 | Papillary | 2.7 | T2N1bM0 | Yes | Yes | IV | Yes | No | – | – | – | – |
| 8 | F | 13 | Papillary | 3.5 | T2N0M0 | No | No | I | No | No | – | – | f | – |
| 9 | F | 33 | Papillary | 1.5 | T1N0M0 | No | No | I | Yes | No | 1+ | f | f | – |
| 10 | F | 43 | Papillary | 2.8 | T2N0M0 | No | No | I | No | No | – | – | – | – |
| 11 | M | 45 | Papillary | 1.0 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 12 | F | 30 | Papillary | 1.4 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 13 | M | 37 | Papillary | 0.5 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 14 | F | 68 | Papillary | 4.5 | T3N0M0 | No | No | III | No | No | – | – | f | – |
| 15 | M | 39 | Papillary | 1.7 | T1N0M0 | No | No | I | Yes | No | – | – | – | – |
| 16 | M | 73 | Papillary | 7.0 | T3N0M0 | No | No | III | No | No | – | – | – | – |
| 17 | M | 47 | Papillary | 0.6 | T1N1aM0 | Yes | Yes | III | No | No | – | – | – | – |
| 18 | F | 51 | Papillary | 2.2 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 19 | F | 48 | Papillary | 1.1 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 20 | F | 71 | Papillary | 4.0 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 21 | M | 62 | Papillary | 5.0 | T3N0M0 | No | No | III | No | No | – | – | – | – |
| 22 | F | 28 | Papillary | 1.6 | T1N0M0 | No | No | I | Yes | No | – | – | – | – |
| 23 | F | 37 | Papillary | 2.8 | T2N0M0 | No | No | I | No | No | – | – | – | – |
| 24 | F | 37 | Papillary | 2.3 | T2N0M0 | No | No | I | No | No | – | – | – | – |
| 25 | F | 66 | Papillary | 2.6 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 26 | F | 47 | Papillary | 1.7 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 27 | F | 46 | Papillary | 1.8 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 28 | F | 41 | Papillary | 2.8 | T2N0M0 | No | No | I | No | No | – | – | – | – |
| 29 | F | 63 | Follicular | 4.0 | T2N0M0 | No | No | II | No | No | 1+ | – | – | 4+ |
| 30 | F | 61 | Follicular | 3.5 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 31 | F | 70 | Follicular | 1.4 | T1N0M0 | No | No | I | No | No | – | – | – | – |
| 32 | F | 44 | Follicular | 2.5 | T2N0M0 | No | No | II | No | No | – | – | – | – |
| 33 | F | 46 | Follicular | 4.5 | T3N0M0 | No | No | III | No | No | – | – | – | – |
| 34 | F | 43 | Follicular | 2.9 | T2N0M0 | No | No | II | No | No | 4+ | – | – | – |
| 35 | F | 33 | Follicular | 3.1 | T2N0M0 | No | No | I | Yes | Yes | – | – | – | – |
| 36 | F | 30 | Follicular | 2.8 | T2N0M0 | No | No | I | No | No | – | – | – | – |
| 37 | F | 50 | Follicular | 4.5 | T3N0M0 | No | No | III | No | No | – | – | – | – |
P, patient number; F, female; M, male; CT antigen, cancer/testis antigen; MAGE-A, melanoma-associated antigen A; MAGE-C1/CT7, melanoma-associated antigen C1; CTAG1B, cancer/testis antigen 1B; GAGE, G antigen; TNM, tumor-node-metastasis; f, focal.